A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) (CAPE)

What is the purpose of this trial?

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.

Participation Guidelines

Ages: 6 - 30 years

Gender: Both

AbbVie Inc.

Start Date: 11/13/2015

End Date: 04/01/2030

Last Updated: 02/22/2018

Study HIC#: 1509016499REG

Get Involved

For more information about this study, contact:
Dinesh Pashankar
+1 203-785-4649

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Dinesh Pashankar

Principal Investigator